君實生物(688180.SH)與康聯達生技設立合資公司 於東南亞多國合作開發和商業化特瑞普利單抗
格隆匯3月28日丨君實生物(688180.SH)公佈，2023年3月27日，公司與Rxilient Biotech Pte. Ltd.(簡稱“康聯達生技”)及其全資子公司Excellmab Pte. Ltd.(簡稱“Excellmab”)訂立股東協議，公司將以非貨幣方式出資認購Excellmab新發行的股份以獲得其40%股權。受限於股東協議項下約定的先決條件達成，公司將實質履行出資義務，並計劃按照訂立股東協議時各方已商定的文本與Excellmab訂立獨佔許可協議，授予Excellmab在泰國、文萊、柬埔寨、印度尼西亞、老撾、馬來西亞、緬甸、菲律賓及越南(簡稱“合作區域”)開發和商業化靜脈注射用特瑞普利單抗的獨佔許可及其他相關權利。
康聯達生技於2021年11月成立於新加坡，為康哲藥業(00867.HK)的控股子公司。康聯達生技及康哲藥業的其他東南亞業務公司(與康聯達生技合稱“康聯達”)是集創新研究、製劑定製研發生產(CDMO)、生產、銷售與推廣為一體的開放性平台。康聯達結合康哲藥業二十多年全球投資併購優質產品的能力、卓越的市場商業化經驗、強勁的自有現金流與領先的風險資本及投融資理念，通過與全球領先的生物醫藥企業合作，將優質的藥品引入東南亞，並最終實現本地生產，探索構建全球製藥產業在東南亞的“橋頭堡”並走向世界。
公司表示，此次交易是公司持續拓展全球商業化網絡的重要實踐，將進一步助力公司產品快速深入東南亞市場。雙方通過設立合資公司的合作模式，結合康聯達的註冊和商業化優勢以及公司雄厚的研發實力，實現優勢互補、強強聯合。特瑞普利單抗為中國創新藥出海的重要品種之一，雙方憑藉此次合作將這一重要創新藥品引入東南亞市場，有望實現中國抗PD-1單抗產品首次在東南亞國家商業化。依託合資公司這一平台，公司也計劃與康聯達進行深入合作，將更多研發的優質創新藥引入東南亞市場，實現雙方的共同、長足發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
